Eupraxia Pharmaceuticals Files 6-K with Financials
Ticker: EPRX · Form: 6-K · Filed: Nov 7, 2024 · CIK: 1581178
Sentiment: neutral
Topics: financials, sec-filing, 6-k
TL;DR
Eupraxia dropped Q3 financials in a 6-K, check F-10 and S-8 filings for more.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on November 7, 2024, incorporating by reference its consolidated financial statements for the three and nine months ended September 30, 2024, and Management's Discussion. These documents are incorporated into its Registration Statements on Form F-10 (File No. 333-276586) and Form S-8 (File No. 333-278534).
Why It Matters
This filing provides investors with updated financial performance data for Eupraxia Pharmaceuticals, crucial for assessing the company's current financial health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not introduce new risks.
Key Numbers
- 9 months — Financial Reporting Period (Consolidated financial statements cover the nine months ended September 30, 2024.)
- 3 months — Financial Reporting Period (Consolidated financial statements cover the three months ended September 30, 2024.)
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Filer
- 0001193125-24-253301 (filing_id) — Accession Number
- 20241107 (date) — Filing Date
- September 30, 2024 (date) — Financial Period End
- 333-276586 (registration_statement_id) — Form F-10 File Number
- 333-278534 (registration_statement_id) — Form S-8 File Number
FAQ
What specific financial information is included in Exhibit 99.1?
Exhibit 99.1 includes the Consolidated Financial Statements for the three and nine months ended September 30, 2024.
What is the purpose of incorporating these exhibits into the Registration Statements?
Exhibits 99.1 and 99.2 are incorporated by reference into the registrant's Registration Statement on Form F-10 (File No. 333-276586) and its Registration Statement on Form S-8 (File No. 333-278534).
What is the filing date of this Form 6-K?
This Form 6-K was filed as of November 7, 2024.
What is the principal executive office address of Eupraxia Pharmaceuticals Inc.?
The principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Which SEC Act is this filing made under?
This filing is made pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 248 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-11-07 17:17:56
Filing Documents
- d910275d6k.htm (6-K) — 11KB
- d910275dex991.htm (EX-99.1) — 434KB
- d910275dex992.htm (EX-99.2) — 332KB
- d910275dex993.htm (EX-99.3) — 19KB
- d910275dex994.htm (EX-99.4) — 12KB
- d910275dex995.htm (EX-99.5) — 12KB
- g910275g1104154441294.jpg (GRAPHIC) — 6KB
- g910275g11a11.jpg (GRAPHIC) — 13KB
- 0001193125-24-253301.txt ( ) — 847KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: November 7, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer